Ann Klopp1, Benjamin D Smith1, Kaled Alektiar2, Alvin Cabrera3, Antonio L Damato4, Beth Erickson5, Gini Fleming6, David Gaffney7, Kathryn Greven8, Karen Lu9, David Miller10, David Moore11, Daniel Petereit12, Tracey Schefter13, William Small14, Catheryn Yashar15, Akila N Viswanathan16. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina. 4. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 5. Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin. 6. Department of Medicine, University of Chicago, Chicago, Illinois. 7. Department of Radiation Oncology, University of Utah, Salt Lake, Utah. 8. Department of Radiation Oncology, Wake Forest University, Winston-Salem, North Carolina. 9. Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 10. Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, Texas. 11. Franciscan Alliance, Mishawaka, Indiana. 12. Regional Cancer Care Institute, Rapid City, South Dakota. 13. Department of Radiation Oncology, University of Colorado Denver, Aurora, Colorado. 14. Department of Radiation Oncology, Stritch School of Medicine, Loyola University, Chicago, Illinois. 15. Department of Radiation Oncology, University of California San Diego, San Diego, California. 16. Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: aviswanathan@lroc.harvard.edu.
Abstract
PURPOSE: To present evidence-based guidelines for adjuvant radiation in the treatment of endometrial cancer. METHODS AND MATERIALS: Key clinical questions to be addressed in this evidence-based guideline on endometrial cancer were identified. A comprehensive literature review was performed to identify studies that included no adjuvant therapy, or pelvic radiation or vaginal brachytherapy with or without systemic chemotherapy. Outcomes included local control, survival rates, and overall assessment of quality of life. RESULTS: Patients with grade 1 or 2 cancers with either no invasion or <50% myometrial invasion (MI), especially when no other high risk features are present, can be safely observed after hysterectomy. Vaginal cuff brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence for patients with grade 1 or 2 cancers with ≥50% MI or grade 3 tumors with <50% MI. Patients with grade 3 cancer with ≥50% MI or cervical stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence. There is limited evidence for a benefit to vaginal cuff brachytherapy following pelvic radiation. Multimodality treatment is recommended for patients with positive nodes or involved uterine serosa, ovaries or fallopian tubes, vagina, bladder, or rectum. CONCLUSIONS: External beam and vaginal brachytherapy remain integral aspects of adjuvant therapy for endometrial cancer.
PURPOSE: To present evidence-based guidelines for adjuvant radiation in the treatment of endometrial cancer. METHODS AND MATERIALS: Key clinical questions to be addressed in this evidence-based guideline on endometrial cancer were identified. A comprehensive literature review was performed to identify studies that included no adjuvant therapy, or pelvic radiation or vaginal brachytherapy with or without systemic chemotherapy. Outcomes included local control, survival rates, and overall assessment of quality of life. RESULTS: Patients with grade 1 or 2 cancers with either no invasion or <50% myometrial invasion (MI), especially when no other high risk features are present, can be safely observed after hysterectomy. Vaginal cuff brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence for patients with grade 1 or 2 cancers with ≥50% MI or grade 3 tumors with <50% MI. Patients with grade 3 cancer with ≥50% MI or cervical stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence. There is limited evidence for a benefit to vaginal cuff brachytherapy following pelvic radiation. Multimodality treatment is recommended for patients with positive nodes or involved uterine serosa, ovaries or fallopian tubes, vagina, bladder, or rectum. CONCLUSIONS: External beam and vaginal brachytherapy remain integral aspects of adjuvant therapy for endometrial cancer.
Authors: Thomas Hogberg; Mauro Signorelli; Carlos Freire de Oliveira; Roldano Fossati; Andrea Alberto Lissoni; Bengt Sorbe; Håkan Andersson; Seija Grenman; Caroline Lundgren; Per Rosenberg; Karin Boman; Bengt Tholander; Giovanni Scambia; Nicholas Reed; Gennaro Cormio; Germana Tognon; Jackie Clarke; Tomasz Sawicki; Paolo Zola; Gunnar Kristensen Journal: Eur J Cancer Date: 2010-07-07 Impact factor: 9.162
Authors: A J Mundt; R McBride; J Rotmensch; S E Waggoner; S D Yamada; P P Connell Journal: Int J Radiat Oncol Biol Phys Date: 2001-08-01 Impact factor: 7.038
Authors: Carien L Creutzberg; Wim L J van Putten; Carla C Wárlám-Rodenhuis; Alfons C M van den Bergh; Karin A J de Winter; Peter C M Koper; Marnix L M Lybeert; Annerie Slot; Ludy C H W Lutgens; Marika C Stenfert Kroese; Henk Beerman; Mat van Lent Journal: J Clin Oncol Date: 2004-04-01 Impact factor: 44.544
Authors: Angeles Alvarez Secord; Laura J Havrilesky; Victoria Bae-Jump; Jeanette Chin; Brian Calingaert; Amy Bland; Teresa L Rutledge; Andrew Berchuck; Daniel L Clarke-Pearson; Paola A Gehrig Journal: Gynecol Oncol Date: 2007-08-06 Impact factor: 5.482
Authors: Henry M Keys; James A Roberts; Virginia L Brunetto; Richard J Zaino; Nick M Spirtos; Jeffrey D Bloss; Andrew Pearlman; Mitchell A Maiman; Jeffrey G Bell Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: Karen M Gil; Stephanie L Pugh; Ann H Klopp; Anamaria R Yeung; Lari Wenzel; Shannon N Westin; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Snehal Deshmukh; Lisa A Kachnic; Deborah W Bruner Journal: Gynecol Oncol Date: 2019-05-16 Impact factor: 5.482
Authors: Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu Journal: Virchows Arch Date: 2021-02 Impact factor: 4.064
Authors: Rudy S Suidan; Weiguo He; Charlotte C Sun; Hui Zhao; Grace L Smith; Ann H Klopp; Nicole D Fleming; Karen H Lu; Sharon H Giordano; Larissa A Meyer Journal: Gynecol Oncol Date: 2019-03 Impact factor: 5.482
Authors: Arya Amini; Peter E DeWitt; Yevgeniy Vinogradskiy; Chad G Rusthoven; Cem Altunbas; Tracey E Schefter; Christine M Fisher Journal: Rep Pract Oncol Radiother Date: 2016-03-02
Authors: Matthew M Harkenrider; Alec M Block; Kaled M Alektiar; David K Gaffney; Ellen Jones; Ann Klopp; Akila N Viswanathan; William Small Journal: Brachytherapy Date: 2016-05-31 Impact factor: 2.362
Authors: I Ríos; A Rovirosa; C Ascaso; I Valduvieco; A Herreros; L Castilla; S Sabater; K Holub; J Pahisa; A Biete; M Arenas Journal: Clin Transl Oncol Date: 2015-12-11 Impact factor: 3.405
Authors: Marina Frimer; Eirwen M Miller; Viswanathan Shankar; Eugenia Girda; Keyur Mehta; Harriet O Smith; Dennis Y S Kuo; Gary L Goldberg; Mark H Einstein Journal: Int J Gynecol Cancer Date: 2018-11 Impact factor: 3.437